New hope for tough prostate cancer? early trial launches
NCT ID NCT07545811
First seen Apr 24, 2026 · Last updated May 20, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug, JANX014, in 43 men with a hard-to-treat type of prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The main goals are to check the drug's safety and find the right dose, while also looking for signs that it might shrink tumors or lower PSA levels. Participants must have tried at least one anti-androgen and one chemotherapy, or be unable to take chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGNashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.